The European Commission approves Novo Nordisk’s Fiasp

Novo Nordisk announced that the European Commission has granted marketing authorization for Fiasp (fast-acting insulin aspart) for the treatment of adult patients with diabetes. The product is a fast-acting insulin which ensures improved mealtime and overall glucose control with a similar safety profile versus NovoRapid. Fiasp will be available in vial, Penfill and FlexTouch pen. Novo Nordisk expects to launch it in the first half of 2017. (Source Novo Nordisk press release)